Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as an important treatment modality for both primary and secondary peritoneal surface cancers. The CRS/HIPEC treatment involves peritonectomy procedures that often are accompanied by visceral organ resections and intestinal anastomoses, followed by perfusion of chemotherapy at 42°C.
1,2 Even at high-volume centers, CRS/HIPEC can be associated with major morbidity in greater than 50% of patients across a variety of organ systems.
3 This morbidity is multifactorial, as it is affected by patient demographics, tumor biology, and extent of treatment.
3,4